
MetaVia Inc MTVA.O:
METAVIA REPORTS POSITIVE STATISTICALLY SIGNIFICANT RESULTS FROM ITS PHASE 1B CLINICAL TRIAL OF DA-1726 IN METABOLIC DISEASE - DEMONSTRATING STRONG GLYCEMIC RESPONSE, SIGNIFICANT DIRECT HEPATIC EFFECTS, ROBUST WEIGHT LOSS AND FAVORABLE SAFETY PROFILE
METAVIA INC - 9.8 CM WAIST CIRCUMFERENCE REDUCTION AT DAY 54 IN STUDY
METAVIA INC - 23.7% REDUCTION IN LIVER STIFFNESS BY DAY 54 IN STUDY
METAVIA INC - 12.3 MG/DL FASTED GLUCOSE REDUCTION BY DAY 54 IN STUDY
METAVIA INC - 9.1% WEIGHT LOSS (21.2 LBS) BY DAY 54 IN STUDY